Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Friday.
BDTX has been the subject of a number of other research reports. Stifel Nicolaus decreased their price target on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, March 7th. HC Wainwright boosted their price target on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the company a "buy" rating in a research note on Tuesday, March 18th. Finally, Wedbush restated an "outperform" rating and set a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday, March 19th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, Black Diamond Therapeutics has an average rating of "Moderate Buy" and an average target price of $14.60.
Check Out Our Latest Stock Analysis on Black Diamond Therapeutics
Black Diamond Therapeutics Price Performance
Shares of NASDAQ:BDTX traded up $0.09 during mid-day trading on Friday, hitting $2.58. The company had a trading volume of 1,653,880 shares, compared to its average volume of 1,530,699. The firm has a fifty day moving average price of $1.76 and a 200 day moving average price of $2.04. The company has a market capitalization of $146.71 million, a PE ratio of -1.94 and a beta of 2.63. Black Diamond Therapeutics has a one year low of $1.20 and a one year high of $6.75.
Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.03. Research analysts expect that Black Diamond Therapeutics will post -1.3 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Black Diamond Therapeutics news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of Black Diamond Therapeutics stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the transaction, the insider now directly owns 2,733,547 shares of the company's stock, valued at $5,658,442.29. The trade was a 67.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.97% of the company's stock.
Hedge Funds Weigh In On Black Diamond Therapeutics
A number of hedge funds have recently bought and sold shares of BDTX. D. E. Shaw & Co. Inc. purchased a new position in Black Diamond Therapeutics during the 4th quarter worth $37,000. Intech Investment Management LLC boosted its holdings in shares of Black Diamond Therapeutics by 49.1% in the 4th quarter. Intech Investment Management LLC now owns 19,247 shares of the company's stock worth $41,000 after buying an additional 6,340 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Black Diamond Therapeutics by 429.6% in the 4th quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company's stock worth $41,000 after buying an additional 15,355 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Black Diamond Therapeutics in the 4th quarter worth about $42,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Black Diamond Therapeutics by 41.8% in the 4th quarter. Wells Fargo & Company MN now owns 20,119 shares of the company's stock worth $43,000 after buying an additional 5,932 shares during the last quarter. 95.47% of the stock is owned by hedge funds and other institutional investors.
About Black Diamond Therapeutics
(
Get Free Report)
Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Black Diamond Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Black Diamond Therapeutics wasn't on the list.
While Black Diamond Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
